Antibodies
23 February 2009
BioInvent and ThromboGenics Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis19 February 2009
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva18 February 2009
FDA Accepts Amgen’s Submission and Files Biologics License Application for Denosumab11 February 2009
Peregrine Pharmaceuticals’ Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study10 February 2009
XOMA and Takeda Expand Collaboration10 February 2009
Progenics Selects Subcutaneous Form of PRO 140, a Novel HIV Antibody Therapy, for Further Development9 February 2009
Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)6 February 2009
UCB’s meeting with U.S. FDA defines path forward for Cimzia(R) in rheumatoid arthritis5 February 2009
GlaxoSmithKile and Genmab Seek European Marketing Authorisation of Arzerra (Ofatumumab) in Advanced Stage Blood Cancer5 February 2009
Ablynx Announces Second Extension of its Nanobody(R) Drug Discovery and Development Aliance4 February 2009
Peregrine Pharmaceuticals’ Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study2 February 2009
Medarex to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drug Application for MEDI-54630 January 2009
GlaxoSmithKline and Genmab submit Arzerra (Ofatumumab) application to FDA for the treatment of advanced stage blood cancer28 January 2009
Medarex Announces Allowance of Investigational New Drug Application for Company’s First Antibody-Drug Conjugate, MDX-120328 January 2009
Goodwin Biotechnology, Inc. Completes GMP Manufacturing of Neogenix Oncology, Inc. Monoclonal Antibody for Upcoming Clinical Trials26 January 2009
Access Pharmaceuticals Presents new Combination Data on the Company s Angiolix(R) Therapeutic Monoclonal Antibody26 January 2009
BioInvent and ThromboGenics Receive Technology Transfer Success Fee from Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)22 January 2009
ZEVALIN(R) Produced 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma Study22 January 2009
New Biologic Stelara(R) Receives Approval in Europe for Treatment of Moderate to Severe Plaque PsoriasisNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports